Exchange: NSE·Updated 04:00 PM GMT+5:30
News
all
press releases
Gland Pharma Secures USFDA Tentative Approval for Generic Lumify Eye Drops
Hyderabad: Gland Pharma Limited has announced that it … the United States. Gland Pharma , headquartered in Hyderabad, is a pharmaceutical company primarily focused … powders, infusions, oncology drugs , and ophthalmic solutions. Gland Pharma is also known …
cityfalcon.com
More News
Gland Pharma Names Dr Jitendra Gangwal Vice President, Research & Development
New Delhi: Gland Pharma has appointed Dr … institutions and leading Indian pharmaceutical companies. Over the course … . Prior to joining Gland Pharma , Dr. Gangwal was associated … . Reddy’s Laboratories, Glenmark Pharmaceuticals , Alkem Laboratories, and FDC …
cityfalcon.com
Brief India: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains and more
In this briefing: Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base 1. Aequitas: Aditya Infotech IPO Lockup Expiry- Has Continued Its Good Run, Dixon Tech Could Book Gains Aditya Infotech Ltd (6596564Z IN) (AIL) raised around US$151m in its IPO in August 2025. The lockup on its pre-IPO investors is set to expire soon. AIL is a CCTV/video surveillance provider company offering a range of advanced video security and surveillance products, technologies and solutions for enterprise and consumer segments under its CP PLUS brand. In this note, we will talk about the lockup dynamics and possible placement. 2. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation.
cityfalcon.com
Brief India: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD and more
In this briefing: LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD SBI Life Insurance Co Ltd - Strong Quarter; Business Momentum to Continue! Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength 1. LG Electronics India (Initiating Coverage): Steering Through Winds of Leadership and Innovation. ADD We initiate coverage on LG Electronics India (LG) with an ADD rating and a TP of INR 1,545 per share, valuing it at 38x Mar-28E AEPS We like LG for its market leadership in core product categories, strong brand equity, consistent technological innovations and product launches, healthy balance sheet, robust return ratios, and low working capital needs LG is a leading player in washing machines, refrigerators, panel televisions, and inverter ACs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.
cityfalcon.com
Brief India: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense and more
In this briefing: Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Gland Pharma Ltd - Visible Turnaround in Cenexi with Strong Base TVS Motor Co Ltd - Twin Growth Drivers: EV Expansion & Export Strength Primer: Jammu & Kashmir Bank (JKBK IN) - Jan 2026 Exencial Industry Tidings 1. Maruti Suzuki Ltd - Export Momentum Supports Growth; Domestic Competition Remains Intense Domestic Market Share & Profitability Outlook: Domestic demand witnessed a sharp inflection in Q3FY26 following the government’s landmark GST reduction, which catalysed industry growth to ~20.5% YoY versus a decline of ~0.4% in H1FY26. MSIL outperformed the industry with domestic volume growth of ~22%, supported by strong traction across small cars and SUVs. Management highlighted a revival in the small car segment, which transitioned from a “red zone” of negative growth to healthy expansion, aided by improved affordability and a 7% rise in first-time buyers, particularly upgrades from two-wheelers.
cityfalcon.com
Gland Pharma Shares Surge Over 9%, Q3 FY26 Profit Rises 28% To ₹261 Crore
Gland Pharma shares surged over 9 percent after Q3 FY26 profit rose 28 percent and revenue grew 23 percent. Strong product launches, higher R&D spending, and heavy trading volumes boosted investor sentiment.The strong stock movement came after the Hyderabad-based drug maker announced its financial results for the third quarter of FY26 after market hours on Wednesday.
cityfalcon.com
Gland Pharma Gets USFDA Approval for Olopatadine Ophthalmic Solution
… Regulations, 2015, Gland Pharma stated that the USFDA approval … United States market. Gland Pharma , established in 1978 and … injectable and ophthalmic-focused pharmaceutical company with operations across … in India. Gland Pharma stated that the approval …
cityfalcon.com
These two companies will sell shovels during India’s semaglutide gold rush
Shaily Engineering Plastics Ltd and Gland Pharma Ltd, involved in the making and filling of injectable pens for semaglutide, stand to win big as patients will need these devices irrespective of which brand of the drug they choose.
cityfalcon.com
Brief India: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale and more
In this briefing: PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Westlife Foodworld Ltd - Resilience Amid Demand Softness; Maintain BUY Auto Monthly Sales Volume - October 2025 NOCIL Ltd - Pricing Pressure Continues; Global Uncertainties Adding to the Woes 1. PVR’s Two-Front War: Defending Premium SPH While Chasing Asset-Light Scale PVR Inox is piloting a full-service "dine-in" cinema concept in Bengaluru, while management confirms a major strategic shift towards an asset-light (FOCO) model for new screen expansion. The dine-in is a defensive move to protect premium Spend Per Head (SPH) against OTT, while the asset-light pivot is move to fix the balance sheet and scale in Tier-2/3. The company is re-engineering its business to be less dependent on its own capital, but its profitability remains entirely dependent on the one thing it cannot control: the content pipeline . 2. Gland Pharma Ltd - Poised for Stronger H2 Momentum; Rating Upgraded to BUY Stable Core and Cenexi Turnaround Drive Revenue Growth: Gland Pharma reported consolidated revenue of Rs 1,487 Cr in Q2FY26, marking a 5.8% YoY growth, in line with our estimates.
cityfalcon.com
Pharma stocks crack, Nifty Pharma Index slips over 2% as Trump unveils 100% tariff: 3 key factors investors must watch
… and patented drugs entering … pharma space include the likes of Natco Pharma , Laurus Labs, Alembic Pharma , Sun Pharma … , Gland Pharma , Ajanta Pharma , and Glenmark Pharmaceuticals … of Indian pharmaceutical exports. …
cityfalcon.com

Advertisement|Remove ads.